Utilization of macrocyclic peptides to target protein-protein interactions in cancer

被引：6

作者：

Yang, Jiawen ^{[1
,2
,3
]}

Zhu, Qiaoliang ^{[1
]}

Wu, Yifan ^{[2
,4
,5
]}

Qu, Xiaojuan ^{[2
,4
,5
]}

Liu, Haixia ^{[2
,5
,6
]}

Jiang, Biao ^{[2
,7
]}

Ge, Di ^{[1
]}

Song, Xiaoling ^{[2
]}

机构：

[1] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China

[2] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China

[3] Shanghai Clin Res & Trial Ctr, Shanghai, Peoples R China

[4] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China

[5] Univ Chinese Acad Sci, Beijing, Peoples R China

[6] ShanghaiTech Univ, Sch Phys Sci & Technol, Shanghai, Peoples R China

[7] Chinese Acad Sci, Shanghai Inst Organ Chem, CAS Key Lab Synthet Chem Nat Subst, Shanghai, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

基金：

中国国家自然科学基金;

关键词：

protein-protein interactions; macrocyclic peptide; cancer; treatment; drug; CXCR4 ANTAGONIST BKT140; HUMAN CD34(+) CELLS; IN-VITRO SELECTION; OPEN-LABEL; PHASE-II; MONTHLY PASIREOTIDE; UBIQUITIN LIGASES; CYCLIC-PEPTIDES; SOMATOSTATIN; INHIBITOR;

D O I：

10.3389/fonc.2022.992171

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Protein-protein interactions (PPIs) play vital roles in normal cellular processes. Dysregulated PPIs are involved in the process of various diseases, including cancer. Thus, these PPIs may serve as potential therapeutic targets in cancer treatment. However, despite rapid advances in small-molecule drugs and biologics, it is still hard to target PPIs, especially for those intracellular PPIs. Macrocyclic peptides have gained growing attention for their therapeutic properties in targeting dysregulated PPIs. Macrocyclic peptides have some unique features, such as moderate sizes, high selectivity, and high binding affinities, which make them good drug candidates. In addition, some oncology macrocyclic peptide drugs have been approved by the US Food and Drug Administration (FDA) for clinical use. Here, we reviewed the recent development of macrocyclic peptides in cancer treatment. The opportunities and challenges were also discussed to inspire new perspectives.

引用

页数：21

共 175 条

[51] The RaPID Platform for the Discovery of Pseudo-Natural Macrocyclic Peptides [J].

Goto, Yuki ;

Suga, Hiroaki .

ACCOUNTS OF CHEMICAL RESEARCH, 2021, 54 (18) :3604-3617

[52] Directed evolution of cyclic peptides for inhibition of autophagy [J].

Gray, Joshua P. ;

Uddin, Md. Nasir ;

Chaudhari, Rajan ;

Sutton, Margie N. ;

Yang, Hailing ;

Rask, Philip ;

Locke, Hannah ;

Engel, Brian J. ;

Batistatou, Nefeli ;

Wang, Jing ;

Grindel, Brian J. ;

Bhattacharya, Pratip ;

Gammon, Seth T. ;

Zhang, Shuxing ;

Piwnica-Worms, David ;

Kritzer, Joshua A. ;

Lu, Zhen ;

Bast, Robert C., Jr. ;

Millward, Steven W. .

CHEMICAL SCIENCE, 2021, 12 (10) :3526-3543

[53]

Gu Y, 2022, METHODS MOL BIOL, P261, DOI 10.1007/978-1-0716-1689-5_14

[54] Target-templated de novo design of macrocyclic d-/l-peptides: discovery of drug-like inhibitors of PD-1 [J].

Guardiola, Salvador ;

Varese, Monica ;

Roig, Xavier ;

Sanchez-Navarro, Macarena ;

Garcia, Jesus ;

Giralt, Ernest .

CHEMICAL SCIENCE, 2021, 12 (14) :5164-5170

[55] A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC) [J].

Hainsworth, John D. ;

Reeves, James A. ;

Mace, Joseph R. ;

Crane, Edward J. ;

Hamid, Oday ;

Stille, John R. ;

Flynt, Amy ;

Roberson, Stephanie ;

Polzer, John ;

Arrowsmith, Edward R. .

TARGETED ONCOLOGY, 2016, 11 (05) :643-653

[56] Deubiquitylating enzymes and drug discovery: emerging opportunities [J].

Harrigan, Jeanine A. ;

Jacq, Xavier ;

Martin, Niall M. ;

Jackson, Stephen P. .

NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (01) :57-77

[57] Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy [J].

Hazama, Daisuke ;

Yin, Yizhen ;

Murata, Yoji ;

Matsuda, Makoto ;

Okamoto, Takeshi ;

Tanaka, Daisuke ;

Terasaka, Naohiro ;

Zhao, Jinxuan ;

Sakamoto, Mariko ;

Kakuchi, Yuka ;

Saito, Yasuyuki ;

Kotani, Takenori ;

Nishimura, Yoshihiro ;

Nakagawa, Atsushi ;

Suga, Hiroaki ;

Matozaki, Takashi .

CELL CHEMICAL BIOLOGY, 2020, 27 (09) :1181-+

[58] The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? [J].

Hejna, M ;

Schmidinger, M ;

Raderer, M .

ANNALS OF ONCOLOGY, 2002, 13 (05) :653-668

[59] Comprehensive computational design of ordered peptide macrocycles [J].

Hosseinzadeh, Parisa ;

Bhardwaj, Gaurav ;

Mulligan, Vikram Khipple ;

Shortridge, Matthew D. ;

Craven, Timothy W. ;

Pardo-Avila, Fatima ;

Retti, Stephen A. ;

Kim, David E. ;

Silva, Daniel-Adriano ;

Ibrahim, Yehia M. ;

Webb, Ian K. ;

Cort, John R. ;

Adkins, Joshua N. ;

Varani, Gabriele ;

Baker, David .

SCIENCE, 2017, 358 (6369) :1461-1466

[60] MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors [J].

Howard, Thomas P. ;

Arnoff, Taylor E. ;

Song, Melinda R. ;

Giacomelli, Andrew O. ;

Wang, Xiaofeng ;

Hong, Andrew L. ;

Dharia, Neekesh, V ;

Wang, Su ;

Vazquez, Francisca ;

Minh-Tam Pham ;

Morgan, Ann M. ;

Wachter, Franziska ;

Bird, Gregory H. ;

Kugener, Guillaume ;

Oberlick, Elaine M. ;

Rees, Matthew G. ;

Tiv, Hong L. ;

Hwang, Justin H. ;

Walsh, Katherine H. ;

Cook, April ;

Krill-Burger, John M. ;

Tsherniak, Aviad ;

Gokhale, Prafulla C. ;

Park, Peter J. ;

Stegmaier, Kimberly ;

Walensky, Loren D. ;

Hahn, William C. ;

Roberts, Charles W. M. .

CANCER RESEARCH, 2019, 79 (09) :2404-2414

← 1 2 3 4 5 6 7 8 9 10 →